Immuneering Corporation, a clinical-stage oncology company, has announced a definitive securities purchase agreement for a private placement expected to generate approximately $25 million in gross proceeds. This transaction involves the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, alongside purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share. The purchase price represents a 15% premium over the company's last reported closing price. The funds will support the continued development of Immuneering's innovative cancer treatments, particularly their Deep Cyclic Inhibitor, atebimetinib. The closing of the private placement is contingent upon customary conditions and is anticipated to occur on or about August 26, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.